NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

ABIVAX Société Anonyme (ABVX) Stock Analysis

ABIVAX Société Anonyme (ABVX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ABVX

$114.79

+$0.76 (+0.66%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABVX with… →

ABVX Key Statistics

As of Sep 4, 2026
Trading
Open
$114.15
Previous Close
$114.04
Day's Range
112.78–115.33
52-Week Range
69.81–148.83
Volume
489.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.25
Valuation
Market Cap
$10.02B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2035.74
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.38
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$336.10M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
87.25M
1-Year Return
+34.18%
Dividend and dates
Earnings Date
September 21, 2026
Avg Volume
1.47M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ABVX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−14.88%
2025+1742.28%
2024−31.59%
2023 (partial year)+28.92%

As of September 4, 2026.

ABVX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$336.10M—
2024$0.00−$176.24M—
2023$0.00−$147.74M—
2022$0.00−$60.74M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$246.06M−$336.10M—
2024$0.00—−$172.98M−$176.24M—
2023$0.00—−$127.38M−$147.74M—
2022$0.00−$50.76M−$51.21M−$60.74M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABVX Valuation vs Biotechnology Median

Median of 656 stocks
MetricABVXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ABIVAX Société Anonyme (ABVX) is capitalised at $10.02B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 80.

The 52-week range on file runs from $69.81 to $148.83. ABVX last closed at $114.79 on September 4, 2026. That is +$0.76 (+0.66%) against the previous close. The latest close sits 64.43% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $336.10M. Profit margin runs at 0%. Trailing earnings per share are −5.38.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2,035.74. On price-to-sales that is 133.4 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is −0.25. Annualized volatility over the trailing 2 years is 422.27%. Over the trailing twelve months the price has returned +34.18%. The stored price history starts on October 20, 2023, and the total return since then is +1,283.01%.

Growth & Income

The record shows no dividend for ABVX.

So far in 2026 the price is −14.88%. The strongest complete calendar year on file is 2025 at +1,742.28%; the weakest is 2024 at −31.59%.

Peer Comparison

ABIVAX Société Anonyme (ABVX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ABIVAX Société Anonyme ABVX $10.02B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. ABIVAX Société Anonyme has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Visit website →